Elpida

History

2025: Ex-head of Roche in Russia Milos Petrovich bought a 2.5% stake in Elpida

Former head of the Russian representative office of the Swiss pharmaceutical company Roche Milos Petrovich acquired a stake in the domestic manufacturer of the HIV drug Elpida. Petrovich became the owner of a 2.5% stake in Elpida LLC, which specializes in the production of antiretroviral drugs for the treatment of HIV infection. The transaction was completed in June 2025.

As writes, a Forbes similar share in the amount of 2.5% was received by citizen Serbia Yulia Ivinitskaya, whose identity remains unknown. At the same time, the Swiss company Apicon, which previously controlled 5% of the capital of the Russian pharmaceutical manufacturer, completely left its ownership structure.

𝓲

Фото: Freepik

General Director of Infoline Analytics Mikhail Burmistrov estimated the market value of Elpida at ₽12-15 billion. Accordingly, the package acquired by Petrovich may cost ₽300 - 375 million. Roche representatives confirmed that Apicon has no ties to their company.

The executive director of RNC Pharma Nikolai Bespalov suggested that the purchase of a share by Petrovich may not be related to investments, but to his motivation to work in the company. The expert noted that the former head of Roche's Russian office is an experienced manager with extensive experience in the pharmaceutical industry.

Bespalov stressed that Petrovich's competencies can be useful to Elpide for effective business development. He allowed an increase in the value of the share in the future and a possible sale of the package in the medium term to fix profits.

Miloš Petrović managed various Roche divisions in Russia from 2000 to 2014. In 2000-2002, he headed the hospital drugs division of the Russian representative office of the company. From 2005 to 2014, he served as CEO of Roche-Moscow and head of Roche's representative office^[1]

Notes